pediapharm Chef de file pharmaceutique en pédiatrie au Canada

Canada's Leading Pediatric Pharmaceutical Company

What's new

Pediapharm Sells its US Rights to Naproxen Suspension in a Transaction Valued at up to Approximately US$4.25 Million

Read more >

Health Canada Upholds Notice of Deficiency-Withdrawal Letter Regarding Easyhaler Budesonide

Read more >

Pediapharm Announces Second Quarter Financial Results; Revenues Increased by 58% vs Same Period Last Year

Read more >


Stock – PDP.V